Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America

Narra J Pub Date : 2021-12-01 DOI:10.52225/narra.v1i3.55
Dott F. Rosiello, Samsul Anwar, Amanda Yufika, Rashed Y. Adam, M. Ismaeil, A. Ismail, Nesrine BH. Dahman, Montacer Hafsi, Manel Ferjani, Farah S. Sami, F. Monib, Subramaniam R, S. Anandu, M. A. Haque, L. E. Ferreto, José TO. Aburto, J. E. Rojas, Seyi S. Enitan, Akele R Yomi, E. Ezigbo, E. Babadi, E. Kakemam, N. Malik, Irfan Ullah, Malik Sallam
{"title":"Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America","authors":"Dott F. Rosiello, Samsul Anwar, Amanda Yufika, Rashed Y. Adam, M. Ismaeil, A. Ismail, Nesrine BH. Dahman, Montacer Hafsi, Manel Ferjani, Farah S. Sami, F. Monib, Subramaniam R, S. Anandu, M. A. Haque, L. E. Ferreto, José TO. Aburto, J. E. Rojas, Seyi S. Enitan, Akele R Yomi, E. Ezigbo, E. Babadi, E. Kakemam, N. Malik, Irfan Ullah, Malik Sallam","doi":"10.52225/narra.v1i3.55","DOIUrl":null,"url":null,"abstract":"\n\nVaccine hesitancy, defined as the reluctance or rejection in receiving a vaccine despite its availability, represents a major challenge to global health efforts aiming to control the ongoing COVID-19 pandemic. Understanding the possible factors correlated with COVID-19 vaccine hesitancy using a refined well-informed approach can be helpful to address the phenomenon. The current study aimed to evaluate COVID-19 vaccine acceptance rates using four hypothetical scenarios of varying levels of vaccine efficacy and safety profiles in ten Asian, African and South American countries. These scenarios included: 95% efficacy and 20% side effects (Vaccine A), 75% efficacy and 5% side effects (Vaccine B); 75% efficacy and 20% side effects (Vaccine C) and 50% efficacy and 5% side effects (Vaccine D). This study used a self-administered online survey that was distributed during February–May 2021. The total number of study respondents was 1337 with countries of residence as follows: India (21.1%), Pakistan (12.9%), Sudan (11.2%), Nigeria (9.3%), Iran (8.2%), Bangladesh and Brazil (7.9%), Chile (7.7%), Tunisia (7.6%), and Egypt (6.2%). The overall acceptance rates for COVID-19 vaccination were variable based on varying degrees of safety and efficacy as follows: 55.6% for Vaccine C, 58.3% for Vaccine D, 74.0% for Vaccine A and 80.1% for Vaccine B. The highest levels of COVID-19 vaccine acceptance were observed in Brazil followed by Chile across the four different safety and efficacy scenarios. The lowest COVID-19 vaccine acceptance rates were reported in Egypt and Tunisia for the low safety scenarios (20% side effects), and the low efficacy scenario (50% efficacy). The study revealed the potential effect of vaccine safety and efficacy on the intention to get COVID-19 vaccination. At the same efficacy level, higher possibility of side effects caused a large drop in COVID-19 vaccine acceptance rate. This indicates the importance of accurate communication regarding vaccine safety and efficacy on attitude towards the vaccine and intentions to get vaccinated. Regional differences in COVID-19 vaccine acceptance were observed with the Middle East/North African countries showing the lowest rates and the South American countries displaying the highest vaccine acceptance rates.\n\n","PeriodicalId":164668,"journal":{"name":"Narra J","volume":"24 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"58","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Narra J","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52225/narra.v1i3.55","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 58

Abstract

Vaccine hesitancy, defined as the reluctance or rejection in receiving a vaccine despite its availability, represents a major challenge to global health efforts aiming to control the ongoing COVID-19 pandemic. Understanding the possible factors correlated with COVID-19 vaccine hesitancy using a refined well-informed approach can be helpful to address the phenomenon. The current study aimed to evaluate COVID-19 vaccine acceptance rates using four hypothetical scenarios of varying levels of vaccine efficacy and safety profiles in ten Asian, African and South American countries. These scenarios included: 95% efficacy and 20% side effects (Vaccine A), 75% efficacy and 5% side effects (Vaccine B); 75% efficacy and 20% side effects (Vaccine C) and 50% efficacy and 5% side effects (Vaccine D). This study used a self-administered online survey that was distributed during February–May 2021. The total number of study respondents was 1337 with countries of residence as follows: India (21.1%), Pakistan (12.9%), Sudan (11.2%), Nigeria (9.3%), Iran (8.2%), Bangladesh and Brazil (7.9%), Chile (7.7%), Tunisia (7.6%), and Egypt (6.2%). The overall acceptance rates for COVID-19 vaccination were variable based on varying degrees of safety and efficacy as follows: 55.6% for Vaccine C, 58.3% for Vaccine D, 74.0% for Vaccine A and 80.1% for Vaccine B. The highest levels of COVID-19 vaccine acceptance were observed in Brazil followed by Chile across the four different safety and efficacy scenarios. The lowest COVID-19 vaccine acceptance rates were reported in Egypt and Tunisia for the low safety scenarios (20% side effects), and the low efficacy scenario (50% efficacy). The study revealed the potential effect of vaccine safety and efficacy on the intention to get COVID-19 vaccination. At the same efficacy level, higher possibility of side effects caused a large drop in COVID-19 vaccine acceptance rate. This indicates the importance of accurate communication regarding vaccine safety and efficacy on attitude towards the vaccine and intentions to get vaccinated. Regional differences in COVID-19 vaccine acceptance were observed with the Middle East/North African countries showing the lowest rates and the South American countries displaying the highest vaccine acceptance rates.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
亚洲、非洲和南美洲10个国家接受不同假设效力和安全水平的COVID-19疫苗接种
疫苗犹豫是指尽管有疫苗,但仍不愿或拒绝接种疫苗,这是旨在控制当前COVID-19大流行的全球卫生努力面临的重大挑战。通过完善的信息灵通方法了解与COVID-19疫苗犹豫相关的可能因素,有助于解决这一现象。目前的研究旨在评估10个亚洲、非洲和南美国家的COVID-19疫苗接受率,采用四种不同水平疫苗效力和安全性的假设情景。这些情景包括:95%的疗效和20%的副作用(疫苗A), 75%的疗效和5%的副作用(疫苗B);75%的有效性和20%的副作用(疫苗C)和50%的有效性和5%的副作用(疫苗D)。这项研究使用了一项自我管理的在线调查,该调查于2021年2月至5月进行。研究受访者总数为1337人,其居住国如下:印度(21.1%)、巴基斯坦(12.9%)、苏丹(11.2%)、尼日利亚(9.3%)、伊朗(8.2%)、孟加拉国和巴西(7.9%)、智利(7.7%)、突尼斯(7.6%)和埃及(6.2%)。根据不同的安全性和有效性,COVID-19疫苗接种的总体接受率不同:疫苗C为55.6%,疫苗D为58.3%,疫苗A为74.0%,疫苗b为80.1%。在4种不同的安全性和有效性情景中,巴西的COVID-19疫苗接受率最高,其次是智利。埃及和突尼斯报告的最低COVID-19疫苗接种率为低安全性情景(20%副作用)和低有效性情景(50%有效性)。该研究揭示了疫苗安全性和有效性对COVID-19疫苗接种意愿的潜在影响。在相同的疗效水平下,较高的副作用发生可能性导致疫苗接受率大幅下降。这表明就疫苗安全性和有效性、对疫苗的态度和接种意愿进行准确沟通的重要性。在COVID-19疫苗接受率方面存在区域差异,中东/北非国家的疫苗接受率最低,南美国家的疫苗接受率最高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Factors associated with cognitive impairment and the quality-of-life among COVID-19 survivors working as healthcare workers Fatigue in healthcare workers with mild COVID-19 survivors in Indonesia Nearly catastrophe coronary perforation: Is it second drug-eluting stent effective? Effects of metformin and silodosin as supplementary treatments to abiraterone on human telomerase reverse transcriptase (hTERT) level in metastatic castration-resistant prostate cancer (mCRPC) cells: An in vitro study Effect of moringa extract on parasitemia, monocyte activation and organomegaly among Mus musculus infected by Plasmodium berghei ANKA
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1